Prescribing Information
PATIENT SITE

DARZALEX FASPRO® DOSING & ADMINISTRATION GUIDE
DARZALEX® DOSING & ADMINISTRATION GUIDE
PERSEUS Trial:
See Results

INDICATIONS AND DOSING
- Newly Diagnosed
  - DRd
  - DVMP
  - DVTd
- Relapsed or Refractory

NCCN RECOMMENDATIONS

PROVEN EFFICACY

DEMONSTRATED SAFETY

HIGH-RISK SUBGROUP

FRAILTY SUBGROUP

CONTINUING DRd TREATMENT

MAINTAINING TREATMENT BENEFITS

TIME TO DEEPEST RESPONSE

SUSTAINING RESPONSE

SAFETY OVER TIME

ADVANCING PATIENT CARE

ADDITIONAL CLINICAL TRIALS

DARZALEX^®: NEWLY DIAGNOSED

DARZALEX^®: RELAPSED OR REFRACTORY

DARZALEX FASPRO^®: NEWLY DIAGNOSED

DARZALEX FASPRO^®: RELAPSED OR REFRACTORY

DARZALEX FASPRO^®: SUB-Q vs IV

PRACTICE SUPPORT

PATIENT SUPPORT

MECHANISM OF ACTION

FOR APPs & NURSES

PRESCRIBING INFORMATION

DARZALEX FASPRO^® Prescribing Information

DARZALEX FASPRO^® la información de prescripción

DARZALEX^® Prescribing Information

Important Safety Information

DARZALEX FASPRO^® Important Safety Information

DARZALEX^® Important Safety Information

Email Medical Information Center

Search Janssen MD

Dosing & Administration Guide

DARZALEX FASPRO^® Dosing & Administration Guide

DARZALEX^® Dosing & Administration Guide

PATIENT SITE
JANSSEN MYELOMA TREATMENTS
This site is intended for
US healthcare professionals.

DARZALEX FASPRO^® + VRd is FDA-approved for a new indication

Site Map

Home
Site Map

Product Use
Frontline DRd
Continuing DRd treatment
Additional Clinical Trials
Resources
For APPs and Nurses

Medical Information Center

|

Site Map

No footer content content fetched

Last updated August 2024 | cp-233680v4

No footer links content fetched